325 milligrams or less

Subscribe Now Choose a package that suits your preferences.
Start Free Account Get access to 7 premium stories every month for FREE!
Already a Subscriber? Current print subscriber? Activate your complimentary Digital account.

LOS ANGELES — The Food and Drug Administration asked doctors, dentists, pharmacists and other health care professionals to stop giving patients high-dose acetaminophen, the active ingredient in the popular pain-reliever Tylenol.

LOS ANGELES — The Food and Drug Administration asked doctors, dentists, pharmacists and other health care professionals to stop giving patients high-dose acetaminophen, the active ingredient in the popular pain-reliever Tylenol.

Pills, capsules, tablets, syrups and other formulations that contain more than 325 milligrams of acetaminophen have not been shown to reduce pain better than lower doses of the medication; however, such high levels of the drug can cause liver damage, the FDA explained in a recommendation issued Tuesday.

Pharmacists asked to fill prescriptions for medications with more than 325 mg of acetaminophen should contact the doctor or dentist who ordered it and see if a lower dose would suffice, the recommendation said.

As explained by Harvard Medical School’s Family Health Guide, most acetaminophen is broken down into harmless substances removed from the body in urine.

“But a small percentage is rendered into a compound that’s extremely harmful to cells,” the guide says.

The compound is known by the acronym NAPQI, and it’s combined with an antioxidant called glutathione to make it safe to ingest. But in the case of an overdose, there’s “not enough glutathione to sop up NAPQI,” making liver damage a threat.

Three years ago, FDA regulators asked drug manufacturers to voluntarily reduce the amount of acetaminophen in powerful medicines such as Percocet and Vicodin that also contain opioids or other painkillers.

The FDA set a target date of Jan. 14. As of Tuesday, more than half of the manufacturers contacted complied with the request, according to the agency. Regulators will take steps to withdraw their approval of drugs containing more than 325 mg of acetaminophen “in the near future,” according to the statement.